Onkológia 6/2019
Treatment of patients with FLT3 positive acute myeloblastic leukemia
Acute myeloid (myeloblastic) leukemia (AML) is a clinically and genetically heterogeneous disease. Significant advances in the genomics and molecular biology of AML have led to a significantly better understanding of the pathogenesis of the disease, but therapies have not changed significantly over the past decades. The results of standard systemic combination chemotherapy are unsatisfactory particularly in patients at high risk such as patients with a positive FLT3 (FMS-like tyrosine kinase 3) mutations. These mutations are one of the most common mutations in adult patients with AML (approximately presnt in about 20-30% of patients) having a negative effect on patient survival. In this article, we discuss the treatment of patients with FLT3 positive AML with a focus on combining targeted therapy (FLT3 inhibitors) with standard chemotherapy.
Keywords: acute myeloblastic leukemia, FLT3 mutations, FLT3 inhibitors, target therapy, chemotherapy
